You can buy or sell XBiotech and other stocks, options, ETFs, and crypto commission-free!
XBiotech Inc. Common Stock, also called XBiotech, is a biopharmaceutical company, which engages in development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. Read More Its product pipeline include oncology, infectious diseases, dermatology, and inflammatory disorders. The company was founded by John Simard on March 22, 2005 and is headquartered in Austin, TX.
52 Week High
52 Week Low
Simply Wall StMar 8
Who Has Been Buying XBiotech Inc. (NASDAQ:XBIT) Shares?
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examples of insiders dumping stock prior to a period of weak performance. So we’ll take a look at whether insiders have been buying or selling shares in XBiotech Inc. (NASDAQ:XBIT). What Is Insider Buying? It’s quite normal to see company insiders, such as board members, trading in company stock, from time to time. However, such insiders must disclose their trad...
Associated PressMar 5
Phase 2 Clinical Trial of Bermekimab Shows Potential New Standard of Care for Treatment of Hidradenitis Suppurativa, Including Significant Pain Reduction without Antibiotics
This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. - Significant therapeutic benefit achieved whether or not patients had previously failed treatment with existing FDA-approved biological drug.- 61-63% of patients achieved a positive HiSCR (the accepted measure of disease seve...
Associated PressMar 1
Breakthrough Results from Phase 2 Clinical Trial of Bermekimab in the Treatment of Atopic Dermatitis (AD) to be Presented on March 2, 2019 at American Academy of Dermatology Annual Meeting
-- Rapid and significant reduction in skin lesions, 66% (p<0.001) and 76% (p<0.001) mean reduction in EASI score in 4 and 7 weeks, respectively.
-$0.17 per share